Operationalization of the physical frailty & sarcopenia syndrome: rationale and clinical implementation by Marzetti, E. et al.
Translational Medicine @ UniSa - ISSN 2239-9747 2015, 13(5): 29-32
 
 
 
29 
Università degli Studi di Salerno 
 
 
Abstract - Over the years, different operational 
definitions have been elaborated to identify frail 
older persons, but none of them has received 
unanimous consensus. This, in turn, has hampered 
the clinical implementation of frailty as well as the 
design of targeted interventions. To overcome the 
current limitations in the field, a novel 
operationalization of physical frailty (PF) is 
proposed which grounds its roots in the recognition 
of sarcopenia as its central biological substrate. This 
conceptualization is based on the fact that the clinical 
picture of PF overlaps substantially with that of 
sarcopenia. The two conditions may therefore be 
merged into a new clinical entity, the PF & 
sarcopenia (PF&S) syndrome, in which muscle loss 
represents both the biological substrate for the 
development of PF and a major pathway whereby the 
negative health outcomes of PF occur. All of the 
components defining the PF&S syndrome are 
measurable in an objective manner, which will 
facilitate its incorporation into standard practice. The 
recognition of a precise biological substratum for 
PF&S (i.e., skeletal muscle decline) also opens new 
venues for the development of preventive and 
therapeutic interventions.  
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I.  INTRODUCTION 
 
 Healthcare systems are increasingly faced with a 
growing population of older adults characterized by the 
co-existence of multiple, chronic disabling conditions [1]. 
The gap between the demand of effective intervention 
strategies and the availability of medical programs 
specifically dedicated to older adults results in 
inappropriate use of resources and escalating healthcare 
expenditures [1,2]. Functional dependence, in particular, 
poses a serious threat on the sustainability of healthcare 
systems [3]. Hence, although prolongation of life remains 
a major public health goal, specific strategies should be 
developed to preserve physical function into late life and 
maximize disability-free life expectancy. 
 In this scenario, the geriatric syndromes of frailty 
and sarcopenia have gained special interest due to their 
association with a number of potentially preventable 
adverse health outcomes. These syndromes may therefore 
well serve as paradigmatic conditions around which 
healthcare systems can be re-shaped and optimized to 
address the specific medical needs of older persons [4,5]. 
 Despite the efforts of many researchers, frailty 
and sarcopenia are still "orphan" of firmly established 
operational definitions and evaluation methodologies, and 
this has so far impeded their translation into every-day 
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clinical practice [6]. The ultimate consequence of these 
persisting uncertainties and debate is the lack of effective 
interventions to prevent the development and impede the 
progression of the two conditions. Such an impasse might 
be overcome through the development and validation of a 
conceptual framework specifically elaborated to facilitate 
the translation of frailty and sarcopenia in clinical 
practice. To this aim, the pathophysiological and clinical 
foundations of the two conditions should be precisely 
defined, in order to assist in the design and 
implementation of ad hoc preventive and therapeutic 
interventions. Such an ambitious task represents a major 
objective of the «Sarcopenia and Physical fRailty IN older 
people: multi-componenT Treatment strategies» 
(SPRINTT) study, a research project recently funded by 
the Innovative Medicine Initiatives (IMI) [7]. 
 
II.  PHYSICAL FRAILTY AND SARCOPENIA: AN 
INNOVATIVE THEORETICAL APPROACH 
 
 In the literature, different criteria have been 
proposed to identify frail older persons, which mainly 
refer to two conceptual models: the cumulative deficit 
approach, proposed by Rockwood et al. [8], and the frailty  
phenotype, proposed by Fried et al. [9]. Both models have 
received empirical validation; yet, the frailty phenotype 
has some recognizable advantages, which are probably 
responsible for its more frequent use in the geriatric 
literature. First, it has a solid, well-characterized 
pathophysiological background [9,10]; second, its 
definition, based on only five items, makes it more easily 
applicable than the complex and cumbersome cumulative 
deficit approach; third, and most importantly, it identifies 
frailty at an early stage, before overt disability has 
developed, therefore opening venues to preventing 
interventions. The condition depicted by the frailty 
phenotype is, indeed, predictive of major negative health-
related outcomes, including disability in the domains of 
mobility and self-care (basic activities of daily living), 
institutionalization, and mortality [10]. 
 Although the pathways leading to the 
development of frailty and its progression towards 
disability are complex, and encompass a variety of 
mechanisms besides those centered on muscle structure 
and function, the frailty phenotype shows substantial 
overlaps with the clinical picture of sarcopenia [11]. 
Indeed, physical function impairment represents the inner 
core shared by the two conditions.  Based on this 
observation, a novel operationalization of physical frailty 
(PF) is proposed, which recognizes sarcopenia as its 
central biological substrate [8]. According to this 
proposition, the decline in muscle mass and function 
during aging would represent the pathway through which 
the negative health outcomes of PF ensue [12]. To put it 
differently, sarcopenia may be envisioned as the "organ 
failure" underlying the clinical manifestations of PF [11]. 
It follows that the two conditions may be merged into a 
new clinical entity, the PF & sarcopenia (PF&S) 
syndrome, with important implications for its clinical 
implementation and the development of dedicated 
healthcare initiatives.  
 Notably, all of the components describing the 
PF&S model are measurable and quantifiable. The 
implementation of such a paradigm would therefore allow 
the accurate operationalization of PF&S, a clear 
identification of the affected population, and the rapid 
translation of research findings to the clinical arena. Such 
a conceptualization would also make PF&S comparable to 
other chronic degenerative conditions of old age (e.g., 
chronic obstructive pulmonary disease and congestive 
heart failure) because mirroring the paradigm of a 
biological substratum for a specific set of symptoms/signs 
determining a measurable decreased function [11]. The 
PF&S syndrome may thus gain its spotlight among the 
geriatric "giants" [13], besides becoming easily acceptable 
by healthcare professionals, public health authorities, and 
regulatory bodies. 
 
III.  THE PF&S SYNDROME: FROM "BRAINSIDE" 
TO BEDSIDE 
 
 As previously elaborated, the proposed 
conceptualization of PF&S involves a set of objectively 
measurable domains that encompass the full spectrum of 
the condition, from biological substrate to clinical framing 
(Figure 1). The muscle atrophy component can easily be 
quantified with available techniques (e.g., dual energy X-
ray absorptiometry [DXA]). Through the adoption of 
Classification and Regression Tree (CaRT) models, the 
Foundation for the National Institute of Health (FNIH) 
initiative has recently identified cut-points of low lean 
mass that are associated with increased risk of mobility 
disability [14,15]. It appears then reasonable that FNIH 
criteria, rather than consensus definitions of sarcopenia, be 
used to identify the muscle atrophy component of PF&S. 
 At the clinical level, the manifestations of PF&S 
(e.g., impaired balance, slow gait, muscle weakness) can 
be measured in an objective manner using specific tools, 
such as the Short Physical Performance Battery (SPPB) 
[16-18]. This tool has shown to predict major negative 
health-related events (including disability, 
institutionalization, and mortality), and also provides an 
accurate picture of the "biological age" of an older person 
[16-19]. At the same time, the SPPB is strongly related 
with the quantity and quality of skeletal muscle, and is 
therefore able to capture the core of PF&S [4]. In 
particular, a cutoff of 9 (included) at the SPPB allows the 
identification of older adults at increased risk of adverse 
health events, including reduced quality of life, disability 
and mortality [16,17,20]. 
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IV.  CONCLUSION 
 
 The ongoing demographic transition is 
accompanied by substantial changes in medical needs and 
nosographic scenarios, which imposes the development of 
counteractions against highly prevalent disabling 
conditions. The traditional paradigm of a "standalone-
disease medicine" has clearly become outdated in a 
clinical world dominated by older persons suffering from 
multiple chronic conditions and mutually interacting 
syndromes [21]. On the other hand, although the transition 
from the disease-centered model of care to a "holistic" 
approach is crucial in geriatric care, the identification of 
pathophysiological mechanisms altering key functions for 
the older person (e.g., physical function) and potentially 
usable as targets for interventions are still necessary. The 
operationalization of PF&S herewith proposed surpasses 
the traditional paradigm of healing through treating a 
single disease, and may support the design of future non-
pharmacological and pharmacological strategies aimed at 
improving the older person's health status by focusing on 
the functional domain [11,22,23]. 
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Fig. 1.  Physical frailty and sarcopenia (PF&S): from concept to practice. The PF&S condition can be objectively measured in all its 
domains, spanning from biologic substrate (reduction in muscle mass) up to its clinical manifestations. The muscle domain can be measured 
using standard techniques, such as dual energy X-ray absorptiometry (DXA). The clinical "identikit" of an older person with PF&S can be 
sketched as the "perfect storm" of poor balance, slow gait and muscle weakness. This picture can easily be quantified using specific tools, such as 
the Short Physical Performance Battery (SPPB). 
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